Tmunity
Dr. Carl June is a pioneer in CAR T cell therapy and currently serves as the Richard W. Vague Professor of Immunotherapy in the Department of Pathology and Laboratory Medicine, Director of the Center for Cellular Immunotherapies at the Perelman School of Medicine, and Director of the Parker Institute for Cancer Immunotherapy at the University of Pennsylvania. The CAR T cells invented in the June laboratory were awarded “Breakthrough Therapy” status by the FDA for acute leukemia in children and adults in 2014 and were approved by the FDA for acute leukemia in 2017 and afterwards, for diffuse large B cell lymphoma.
Dr. June has published more than 500 manuscripts and is the recipient of numerous honors, including recognition by the White House (on several occasions) and election to the National Academy of Medicine, the National Academy of Sciences, the American Academy of Arts and Sciences, and the American Philosophical Society.
This person is not in any offices
Tmunity
Tmunity is a unique biotherapeutics company because of the unrivaled depth of its scientific founders’ and management team’s experience and demonstrated field-specific track record, its mastery of the application of gene-editing and cell engineering tools in human trial settings, the maturity of its clinic-ready development programs, the readiness to scale through its manufacturing processes and facility, and the breadth of its relevant clinical, regulatory, commercial and company-building expertise.